A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)

@inproceedings{Pentheroudakis2013ASO,
  title={A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)},
  author={George Pentheroudakis and Vassiliki A Kotoula and Elena Fountzilas and George Kouvatseas and Georgios Basdanis and Ioannis Xanthakis and Thomas Makatsoris and Elpida Charalambous and Dimitrios Papamichael and Epaminontas Samantas and Pavlos Papakostas and Dimitrios I Bafaloukos and Evangelia Razis and Christos Christodoulou and Ioannis I. Varthalitis and Nicholas Pavlidis and George Fountzilas},
  booktitle={BMC Cancer},
  year={2013}
}
Bevacizumab, an antibody neutralizing Vascular Endothelial Growth Factor (VEGF), is licensed for the management of patients with advanced colon cancer. However, tumor biomarkers identifying the molecular tumor subsets most amenable to angiogenesis modulation are lacking. We profiled expession of 24526 genes by means of whole genome 24 K DASL (c-DNA-mediated, Annealing, Selection and Ligation) arrays, (Illumina, CA) in 16 bevacizumab-treated patients with advanced colon cancer (Test set). Genes… CONTINUE READING
8 Citations
36 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Similar Papers

Loading similar papers…